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Background: Reimbursement policies influence access of patients to orphan drugs in
the European countries.
Objectives: To provide a comprehensive description of orphan drug reimbursement
policies and to assess reimbursement decision-making process in the EU-CEE countries
as well as the impact of the type of approval and disease on reimbursement decisions.
Methods: For each drug, the information regarding conditional approval or approval
under exceptional circumstances was obtained from the EMA website. The
reimbursement status for analyzed drugs was collected in a questionnaire survey
performed in a group of experts in reimbursement policy. The agreement between
countries was assessed using the κ coefficient, nominal variables tests were compared
using the χ2 test or the Fisher exact test. The impact of the EMA’s conditional approval
and approval under exceptional circumstances was assessed using logistic regression
and presented as an odds ratio (OR).
Results: The analysis revealed that most orphan drugs were authorized for the
treatment of oncological or metabolic diseases [36 drugs (38%) and 22 drugs (23%),
respectively]. The shares of reimbursed orphan drugs varied significantly (p = 0.0031)
from 6.3% in Latvia to 27.4% in Poland. No correlation (r = 0.02; p = 0.9583) with
GDP per capita was observed. The highest agreement in reimbursement decisions
was observed between Estonia and Lithuania, and the lowest – between Estonia
and Latvia, with kappa of 0.69 and 0.11, respectively. Significant impact of the
type of approval and reimbursement status was observed for Czechia, Lithuania
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and Slovakia where conditional approval and exceptional circumstances negatively
influenced reimbursement decision. Type of disease has significant influence on
reimbursement decision in 4 out of 10 analyzed countries with significant outweigh of
positive decisions for oncological diseases.
Conclusion: In considered countries specific regulations on reimbursement of orphan
drugs are valid but in Lithuania and Romania no formal HTA process was employed;
in case of some countries higher ICER values for orphans are used. The share of
reimbursed orphan drugs varied significantly across the countries, but it was not
associated with GDP per capita.
Keywords: orphan drug, reimbursement policy, Central and East Europe, European Medicine Agency, kappa
coefficient of agreement, marketing authorisation, exceptional circumstances, conditional approval
INTRODUCTION
Rare diseases mostly include inherited life-threatening or
chronically debilitating diseases that affect fewer than 5 out
of 10,000 people, according to the definition issued by the
European Medicines Agency (EMA), however, the definition can
vary between countries. This results in an approximate number
of 246,000 patients affected by rare diseases in 27 European
Union (EU) member countries (European Medicines Agency,
2007; Winstone et al., 2015). Reimbursement of drugs for rare
diseases (so-called orphan drugs – approved by centralized
procedure) is the most important factor that can increase the
accessibility of treatment for patients. The EMA provides three
types of approval: (a) conditional – a temporary approval
until more data from clinical trials are available and the
conditions will be fulfilled; (b) exceptional circumstances – a
status that indicates that it is not possible to obtain additional
data; and (c) approval without additional conditions (European
Commission, 2006; European Medicines Agency, 2018a). Unlike
the conditional approval, in which a marketing approval is
granted on condition that a sponsor will provide relevant data
within an agreed time frame, authorization under exceptional
circumstances can be granted even when the more precise data
will not be available for a more comprehensive assessment
- usually data are further collected via registries instead of
clinical trials. In all situations, the benefit of the product should
outweigh the risk.
Both conditional approval and exceptional circumstances
could influence reimbursement decision-making and should be
considered in reimbursement policies, especially in countries
with a limited budget (European Commission, 2006), such
as the member states that joined the EU in 2004 as mostly
middle- and low-income countries from the Central Eastern
European (CEE) region. The situation has gradually improved
for these countries, as they have expanded their pharmaceutical
shares of health spending at an 8-fold higher annual rate
compared with the 15 original EU countries (EU15; Jakovljevic
et al., 2016). Orphan drugs along with targeted biologics are
considered the most expensive pharmaceuticals (Jakovljevic and
Yamada, 2017); therefore, it is especially important to improve
their availability in CEE countries. Proper allocation of public
resources represents a major challenge for public health and
health care decision-making and seems to be reflected in
substantial differences in reimbursement decisions for orphan
drugs among the EU15 countries (Malinowski et al., 2018).
There are different classes of orphan drugs, with the broadest
classes including oncological drugs [around 32.5% of orphan
drugs (Gammie et al., 2015)] and drugs for metabolic conditions.
Our objective of this study was to assess and compare the
percentage of reimbursed orphan drugs as well as the agreement
in reimbursement decision-making between selected CEE
countries. We also aimed to evaluate if reimbursement decisions
were influenced by whether the EMA granted conditional
approval or approval under exceptional circumstances. The
impact of the type of disease (oncological or metabolic)
on the type of approval (conditional or under exceptional
circumstances) was also examined. Overall, we aimed to provide
a comprehensive review of reimbursement policies for orphan
drugs in EU–CEE countries.
MATERIALS AND METHODS
For each drug, the information regarding conditional approval
or approval under exceptional circumstances was obtained
from the EMA website (European Medicines Agency, 2018b).
The reimbursement status for selected drugs was collected
in a questionnaire survey performed in a group of experts
in reimbursement policy and orphan drugs in the following
EU-CEE countries: Bulgaria, Croatia, Czechia, Estonia, Hungary,
Latvia, Lithuania, Poland, Romania, and Slovakia in 2017–2018.
Data on the reimbursement system and decision-making process
in these countries were also collected. Additional analyses were
performed for the relevant subgroups of drugs used in the
treatment of patients with oncological or metabolic conditions.
Finally, the results for these two subgroups of drugs were
compared with drugs used for the treatment of patients with
other diseases (neither oncological nor metabolic; European
Medicines Agency, 2018b).
The agreement (share of agreed answers over the expected at
random) between countries was assessed using the κ coefficient,
with values lower than 0 denoting less than chance agreement;
between 0.01 and 0.20, slight agreement; between 0.21 and 0.40,
fair agreement; between 0.41 and 0.60, moderate agreement;
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between 0.61 and 0.80, substantial agreement; and between 0.81
and 0.99, almost perfect agreement (Viera and Garrett, 2005). All
κ coefficients were supported with 95% confidence intervals (CIs)
and rounded to 2 decimal places.
Two nominal variables were performed using the χ2 test or the
Fisher exact test, as applicable, depending on expected cell counts
in contingency tables. The results of the tests were presented as
p-values rounded to 4 decimal places. The data were summarized
with counts and percentages.
The impact of the EMA’s conditional approval and approval
under exceptional circumstances was assessed using logistic
regression and presented as an odds ratio (OR) showing the
odds for reimbursement when these types of approval were
granted compared with no conditional approval or approval
under exceptional circumstances. Logistic regression was also
used to investigate the impact of the type of disease on positive
reimbursement decisions. All ORs were presented with 95% CIs
rounded to 2 decimal places and with corresponding p-values
rounded to 4 decimal places. A p-value of less than 0.05
was considered statistically significant. Statistical analyses were
carried out in the JMP R© software, version 14.0.0 (SAS Institute
Inc., 2018, Cary, NC, United States).
RESULTS
The reimbursement status of 95 orphan drugs was assessed. The
analysis revealed that most orphan drugs were authorized for
the treatment of patients with oncological or metabolic diseases
(36 drugs (38%) and 22 drugs (23%), respectively; Table 1]. The
shares of reimbursed orphan drugs varied significantly (p-value
of 0.0031) from a minimum of 6.3% in Latvia to a maximum
of 27.4% in Poland (Figure 1). We observed that the shares
of reimbursed orphan drugs experienced a trend with the total
gross domestic product (GDP; correlation of 0.53), although the
result was not significant (p-value of 0.1185). Additionally, no
correlation (correlation of 0.02; p-value of 0.9583) was observed
when analyzing GDP per capita (Figure 1).
Comparative Summary of Orphan Drug
Reimbursement Policy
Half of analyzed countries implemented special regulations
regarding (including different sources of payment or
relaxed reimbursement requirements like higher thresholds)
the reimbursement of orphan drugs. In most countries,
the marketing authorization holder (MAH) applies for
reimbursement of a particular drug; however, in Estonia
and Lithuania, applications by doctors’ or patients’ organizations
are also possible. Reimbursement decisions are made mostly by
bodies responsible for health policies in individual countries,
e.g., ministries of health (MoH). In some countries, other bodies
are also included in the reimbursement decision-making process.
In all analyzed countries the list of reimbursed drugs is publicly
available (Table 2).
A full or simplified health technology assessment (HTA) of a
submitted application should be performed with reimbursement
application in most analyzed countries except Romania and
Lithuania. In Romania, the system is based on score cards
that consider the reimbursement status of a particular drug in
other countries (United Kingdom, Germany, and France), and
in Lithuania there is a formal HTA process implemented but it
does not include economic assessment. This is why in some of
those countries HTA is limited to the assessment of clinical data
in other it also includes analysis of cost-effectiveness, e.g., ICER
and/or quality-adjusted life year (QALY; or Life Years Gained –
LYG). In all other countries ICER providing information
on marginal cost per QALY is employed in reimbursement
decision-making, but no higher threshold value is implemented
for orphan drugs compared with non-orphan drugs (Table 3).
The Agreement in Reimbursement
Decisions
The highest agreement in reimbursement decisions was observed
between Estonia and Lithuania, and the lowest – between Estonia
and Latvia, with kappa coefficients of 0.69 and 0.11, respectively.
In all pairwise comparisons the agreement was higher than 0;
however, in a few pairs the lower bound of the confidence
interval was negative, which indicated that there was no observed
agreement in reimbursement decisions between those countries
(Czechia and Romania, Estonia and Latvia, Estonia and Romania,
Hungary and Romania, Romania and Slovakia; Table 4).
Reimbursement Decisions in the Context
of the Type of Authorization and Disease
In total, 14 drugs (14.74%) were approved conditionally and
another 14 drugs (14.74%) were approved under exceptional
circumstances. The type of authorization was associated with the
type of disease (p-value of 0.0053). Medicinal products for the
treatment of genetic metabolic disorders were usually authorized
under exceptional circumstances, and oncological drugs – under
conditional approval (Table 5).
The reimbursement status was significantly associated with
the type of approval only in the Czechia, Lithuania, and
Slovakia. In those countries no drugs approved conditionally
were reimbursed (out of all analyzed drugs – other conditionally
approved drugs could be reimbursed like Erivedge for advanced
basal cell carcinoma was in The Czechia); however, in other
countries at least one drug that was conditionally approved
was reimbursed. In Lithuania, Slovakia, and Latvia, no drugs
approved under exceptional circumstances were reimbursed –
however, they may be available on patient bases, because of rarity
of the disorder (Table 6).
The relationship between the type of disease and the
reimbursement status was significant in Croatia, Estonia,
Hungary, and Lithuania (Table 7). In all those countries, most
reimbursed drugs were indicated for the treatment of oncological
diseases. Logistic regression supports these results and in Croatia,
oncological orphan drugs were more than five times more likely
to be reimbursed compared with the remaining drugs (OR of
5.33; 95%CI: 1.31–21.68; p-value of 0.0124). In Estonia the odds
for reimbursement were 90% lower for metabolic than for other
orphan drugs (OR of 0.10; 95%CI: 0.01–0.82; p-value of 0.0314).
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FIGURE 1 | Relationship between share of reimbursed orphan drugs among analyzed countries and total gross domestic product (GDP) and GDP per capita with
trend line.
Reimbursement Policy in Analyzed
Countries
In Bulgaria, the reimbursement requirements for orphan drugs
are the same as for other medicinal products; the initiative for
reimbursement is only by MAH. The National Council on Prices
and Reimbursement of Medicinal Products is responsible for
the final decision about the reimbursement and the level of
reimbursement. Most orphan drugs are paid from the budget
of the National Health Insurance Fund, but some are paid
from hospital budgets. Orphan drugs need to be included
in Annex I (or Annex II) of the publicly available Positive
Drug List. The reimbursement level depends on the type of
disease, type of treatment (essential, symptomatic, palliative, or
other), and budget resources allocated for procurement of the
medicinal product. The level or reimbursement for orphan drugs
is usually 100% or, in some rare cases, 75%. In the process
of reimbursement, the decision-maker performs an additional
assessment based on the severity of a rare condition, the
availability of an alternative product, and the cost for the patient
if the medicinal product is not reimbursed. The process also
considers if the drug has an orphan status which mean the drug
has a great social benefit and their use is indicated for serious
conditions for which there is no effective alternative therapy.
For Bulgaria, the ICER value is not published in normative
documents such as regulations and law. The National Council
on prices and reimbursement has published methodological
recommendations on documentation presented for assessment
of the efficacy, safety and pharmacoeconomic parameters of
medicinal products applying for inclusion in the Positive Drug
List. The pharmacoeconomic analysis shall indicate whether
the medicinal product is cost-effective using the World Health
Organization’s CHOICE programme (Choosing Interventions
that are Cost-Effective). The result must be presented as GDP
in Bulgarian currency and in the purchasing power standard
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(adjusted by the purchasing power parity), according to official
data published by the National Statistical Institute (Tables 2, 3).
In Croatia, drugs for rare diseases are delivered through
hospitals. There is a special fund (part of the Croatian
Health Insurance Fund [CHIF]) for orphan drugs. The
reimbursement of these drugs will not burden a hospital
budget. Orphan drugs included in the essential list of drugs
of the CHIF are completely reimbursed, while those included
in the additional list are partially reimbursed. During the
reimbursement application process, a budget impact analysis
should be provided. A cost-effectiveness analysis, a clinical
analysis, or an expert opinion can be additionally provided if
needed. The ICER value is important or even essential in the
reimbursement decision; in some cases, there is a need to provide
additional budget impact analysis results (Tables 2, 3).
In The Czechia, the State Institute for Drug Control
(a governmental regulatory agency) decides on pricing and
reimbursement of drugs used in outpatient (ambulatory) care.
However, SUKL does not decide on drugs used in in-patient
(hospital) care. These drugs are reimbursed from hospital
budgets (based on agreements between hospitals and health
insurance funds). In the context of orphan medicines, it is
important to note that if any medicine is not approved to
be reimbursed from any reason, it can still be reimbursed on
individual patient request if this is the only treatment available
for the individual patient taking account of his/her clinical state.
In this case, the reimbursement of this medicine needs to be
pre-approved by the patient’s health insurance fund. Several
entities could apply for reimbursement: a MAH (for authorized
medicinal products), an importer or domestic manufacturer (for
foods for special medical purposes or non-registered medical
products used in the Czechia within a specific treatment
program), and health insurance companies. The budget impact
analysis is required in the HTA process, and the cost-effectiveness
analysis is required in most cases. In some cases, a similar
efficacy and safety profile of applicant drug in relation
to comparators make a cost-minimization analysis possible.
HTA analyses are required in all cases when reimbursement
conditions are broadened (such as new indications, fewer
restrictions on target patient groups) in comparison with the
current state or a therapeutically interchangeable intervention.
The ICER value is important in decision-making except for
temporary reimbursement applications granted for a minimum
of 2 years, renewable for another year. Usually, medicines with
temporary reimbursement are highly innovative products (i.e.,
new medicines for very serious diseases with an unmet medical
need). The current legislation does not define a threshold for
ICER. However, during the HTA process, the State Institute for
Drug Control compares the ICER of the assessed technology with
the ICERs of already reimbursed technologies (used for similar
indications or similar patient groups). The usual ICER used in
line with the institute’s decision-making practice is 1.2 million
CZK per QALY (about 44,500 EUR per QALY; Tables 2, 3).
Estonia has not implemented special reimbursement
legislation for orphan drugs. For all drugs reimbursement
decisions are performed by the Ministry of Social Affairs
and the funding is provided by the Health Insurance TA
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Fund. Only MAH or doctors’ organizations can apply for
reimbursement, and a full HTA dossier is required for orphan
drugs. However, ICER is important in the decisions-making
process not specific threshold are defined neither for orphan nor
non-orphan drugs.
In Hungary, there is no separate legislation for orphan drugs;
however, some policies apply particularly to this drug class, such
as acceptability of cost-effectiveness or importance of the role of
equity. One of the entities that can apply for the reimbursement of
an orphan drug is an HTA committee established by the National
Institute of Health Insurance Fund Management. The other
route is through the Ministry of Human Capacities: the National
Institute sends a recommendation on drug reimbursement to the
Ministry; for new active substances, it is necessary to amend the
law for the reimbursement (e.g., in the case of a new indication).
The Ministry is in charge of the amendment. In most cases,
the representative of the MAH, but sometimes the MAH itself,
applies for a reimbursement dossier. The value of ICER is a
very important criterion, but there are more criteria that must
be considered such as equity, budget impact, or the disease
severity. The ICER cannot be higher than 3 times the GDP
per capita; however, there is no separate threshold for orphan
drugs (Tables 2, 3).
Latvia does not have any special legislation regarding
orphan drugs. Orphan medicines are partially available via the
positive reimbursement list; some orphans are available as a
part of the special programme of rare diseases for Children’s
University Hospital, Riga. Some orphan drugs are provided
within individual reimbursement with limitation up to 14,228.72
euro/year for a single patient. The reimbursement process is
started by the holder of a registration certificate, an authorized
representative, or a wholesaler by submitting by submitting a
full dossier. If orphan drugs are submitted to be reimbursement
in the Positive list or individual reimbursement the decision is
made by The National Health Service of Latvia. If an orphan
drug is used to treat the very rare disease the decision is made
by the Committee. In all cases, the applicant should provide
clinical, cost-effectiveness, and the budget impact analyses.
The ICER value is important in the decision-making process.
The calculation of the costs for one unit of an additionally
obtained result of therapeutic efficacy (ICER), the coefficient
of expansion of cost-effectiveness for a life-year gained or a
progression-free survival do not exceed the three times the
GDP per capita. The economic analysis also takes into account
the proof of the cost-effectiveness of the medicinal products
in the health care system at large or for a specific group of
patients (Tables 2, 3).
Lithuania implemented separate legislation for orphan drugs
for very rare diseases. Only a drug used for an ultra-rare disease
(defined in Lithuania as a disease or human health condition
with one newly diagnosed case per 200,000 inhabitants per
year) can be reimbursed. If orphan drugs are applicable to
be reimbursement in the Positive list the decision is made
by the Reimbursement committee. If an orphan drug is used
to treat the ultra-rare disease the decision is made by The
Ultra-rare diseases reimbursement Committee according to the
doctor’s application. The MAH, as well as doctors’ or patients’
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TABLE 5 | Relationship between type of the disease and type of approval in European Union.
Disease type Conditional
Approval
Exceptional
Circumstances
Unconditional Total p-value (FET)
Metabolic 0 (0.00%) 7 (31.82%) 15 (68.18%) 22 0.0053∗
Oncological 9 (25.00%) 2 (5.56%) 25 (69.44%) 36
Other 5 (13.51%) 5 (13.51%) 27 (72.97%) 37
Total 14 14 67 95
p-value less than 0.05 is marked with an asterisk. FET, Fisher Exact Test.
TABLE 6 | Relationship between reimbursement status and type of approval in Central Eastern European countries.
Country Reimbursement
status
Conditional
Approval
Exceptional
Circumstances
Unconditional Total p-value
Bulgaria Reimbursed 3 (12.50%) 3 (12.50%) 18 (75.00%) 24 0.8568
Not reimbursed 11 (15.49%) 11 (15.49%) 49 (69.01%) 71
Croatia Reimbursed 2 (18.18%) 1 (9.09%) 8 (72.73%) 11 0.8279
Not reimbursed 12 (14.29%) 13 (15.48%) 59 (70.24%) 84
Czechia Reimbursed 0 (0.00%) 2 (8.00%) 23 (92.00%) 25 0.0161∗
Not reimbursed 14 (20.00%) 12 (17.14%) 44 (62.86%) 70
Estonia Reimbursed 2 (8.33%) 2 (8.33%) 20 (83.33%) 24 0.2817
Not reimbursed 12 (16.90%) 12 (16.90%) 47 (66.20%) 71
Hungary Reimbursed 2 (10.00%) 1 (5.00%) 17 (85.00%) 20 0.2506
Not reimbursed 12 (16.00%) 13 (17.33%) 50 (66.67%) 75
Latvia Reimbursed 1 (16.67%) 0 (0.00%) 5 (83.33%) 6 0.5744
Not reimbursed 13 (14.61%) 14 (15.73%) 62 (69.66%) 89
Lithuania Reimbursed 0 (0.00%) 0 (0.00%) 16 (100.00%) 16 0.0179∗
Not reimbursed 14 (17.72%) 14 (17.72%) 51 (64.56%) 79
Poland Reimbursed 2 (7.69%) 3 (11.54%) 21 (80.77%) 26 0.3704
Not reimbursed 12 (17.39%) 11 (15.94%) 46 (66.67%) 69
Romania Reimbursed 1 (4.76%) 3 (14.29%) 17 (80.95%) 21 0.3264
Not reimbursed 13 (17.57%) 11 (14.86%) 50 (67.57%) 74
Slovakia Reimbursed 0 (0.00%) 0 (0.00%) 19 (100.00%) 19 0.0070∗
Not reimbursed 14 (18.42%) 14 (18.42%) 48 (63.16%) 76
Total 14 14 67 95
p-values less than 0.05 are marked with an asterisk.
organizations, could apply for reimbursement of orphan drugs.
However, in the case of drugs for ultra-rare diseases, only the
doctor’s application for reimbursement for an individual patient
is acceptable. Reimbursement may depend on the prevalence
of the disease (orphan drug vs. oncology drug) and on the
application (there may be that the MAH has not applied
for reimbursement). The HTA process in Lithuania is not
implemented yet, but in its application for a drug to be
included in the positive list, the MAH should provide clinical,
cost-effectiveness, and the budget impact analyses. If doctors
apply to the Committee for reimbursement of drugs used
for ultra-rare disease, they should provide information on the
patient’s clinical condition and substantiation of orphan drug use
(Tables 2, 3).
Poland does not implement any separate legislation for
orphan drugs, which are treated as ordinary medications.
However, such drugs could be reimbursed for individual
patients. If it is the case an approval is granted by the
Ministry of Health, a drug is financed from a hospital budget.
Multi-criteria decision analysis (MCDA) is considered as a
strategic direction indicating an additional element in the
decision-making process for orphan drugs reimbursement
in Poland (Ministry of Health, 2019). The key policy maker
and the regulator in the health care system in Poland is
the Ministry of Health, supported by advisory bodies. The
AOTMiT is an independent legal entity that collects data and
delivers statements and recommendations on technologies
claiming public funding, of which predominant are drugs.
The Transparency Council, which is an independent advisory
body consisting of 20 highly qualified members providing
opinions for applicant drugs. The final reimbursement
decisions are taken independently by the Minister of Health,
and the decisions do not have to comply with statements
or recommendations issued by the Transparency Council
or the President of the AOTMiT. Poland implements
external reference pricing, internal reference pricing,
value-based pricing and negotiations when establishing price of
drugs (Tables 2, 3).
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TABLE 7 | Relationship between reimbursement status and type of rare disease in analyzed Central Eastern European countries.
Country Reimbursement
status
Metabolic Oncological Other Total p-value
Bulgaria Reimbursed 4 (16.67%) 13 (54.17%) 7 (29.17%) 24 0.1639
Not reimbursed 18 (25.35%) 23 (32.39%) 30 (42.25%) 71
Croatia Reimbursed 1 (9.09%) 8 (72.73%) 2 (18.18%) 11 0.0403∗
Not reimbursed 21 (25.00%) 28 (33.33%) 35 (41.67%) 84
Czechia Reimbursed 5 (20.00%) 10 (40.00%) 10 (40.00%) 25 0.9069
Not reimbursed 17 (24.29%) 26 (37.14%) 27 (38.57%) 70
Estonia Reimbursed 1 (4.17%) 13 (54.17%) 10 (41.67%) 24 0.0259∗
Not reimbursed 21 (29.58%) 23 (32.39%) 27 (38.03%) 71
Hungary Reimbursed 0 (0.00%) 12 (60.00%) 8 (40.00%) 20 0.0104∗
Not reimbursed 22 (29.33%) 24 (32.00%) 29 (38.67%) 75
Latvia Reimbursed 0 (0.00%) 4 (66.67%) 2 (33.33%) 6 0.2306
Not reimbursed 22 (24.72%) 32 (35.96%) 35 (39.33%) 89
Lithuania Reimbursed 0 (0.00%) 10 (62.50%) 6 (37.50%) 16 0.0231∗
Not reimbursed 22 (27.85%) 26 (32.91%) 31 (39.24%) 79
Poland Reimbursed 4 (15.38 15 (57.69 7 (26.92 26 0.0507
Not reimbursed 18 (26.09%) 21 (30.43%) 30 (43.48%) 69
Romania Reimbursed 5 (23.81%) 9 (42.86%) 7 (33.33%) 21 0.8194
Not reimbursed 17 (22.97%) 27 (36.49%) 30 (40.54%) 74
Slovakia Reimbursed 4 (21.05%) 10 (52.63%) 5 (26.32%) 19 0.3043
Not reimbursed 18 (23.68%) 26 (34.21%) 32 (42.11%) 76
Total 22 36 37 95
p-values less than 0.05 are marked with an asterisk.
The case of Romania is fundamentally different, orphan
drugs being included in a therapeutic program for the rare
disease. MAH submits the file of the product to the National
Drug and Medical Device Agency (NDMDA). The evaluation
consists mainly of allocating to every drug several points for its
reimbursement status in the United Kingdom, Germany, and
France. Orphan drugs are receiving a bonus score comparative
with other molecules. This is so called Score cards method.
The Government approves the NDMDA’s recommendation
through a Government Decision published in the Official
Gazette of Romania. After issuing a therapeutic protocol for
the new drug the reimbursed status becomes effective by the
National Health Insurance House (NHIH) and MoH jointly
order (Tables 2, 3).
Slovakian reimbursement decisions were in 2017 based on
thresholds (commonly described with the Greek letter “λ”)
set forth by Act No. 363/2011 Z. z. The lower threshold
(λ1) was defined as 24 times the average monthly salary
(21,192 EUR/QALY), and the upper threshold (λ2), as 35
times the average monthly salary (30.905 EUR/QALY). The
medicine was reimbursed from public health insurance (fully
or partially) if the incremental costs were lower or equal
to λ1 per one QALY. The medicine was conditionally
reimbursed if the incremental costs lied within λ1 and
λ2 thresholds per one QALY. Medicinal products whose
additional costs per QALY exceeded the upper λ2 threshold
should not be included in the reimbursement list. These
thresholds were not applicable for orphan drugs indicated
for therapy of rare diseases with prevalence lower than
1:100,000 in Slovakia.
Based on the new Slovak legislation (updated Act No.
363/2011 Z. z.), which came into the force in January 1st 2018,
Slovakian reimbursement decisions was in 2018 based on the
following thresholds:
• lower threshold (λ1): 35 times average monthly salary (total
31.920 EUR/QALY);
• upper threshold (λ2): 41 times average monthly salary (total
37.392 EUR/QALY).
In general, the medicine is reimbursed from public health
insurance (fully or partially) if the incremental costs were lower
or equal to λ1 per one incremental QALY. In defined cases could
be the thresholds per one incremental QALY increased up to λ2.
Based on the Slovak legislation, which came into the force
in January 1, 2018, the cost – effectiveness thresholds were
not used in 2018 for medicines in the following cases: an
applicant do not need to attach a pharmacoeconomic analysis
for the decision making procedure at the Slovak Ministry of
Health concerning to reimbursement from the public health fund
in the case that a medicinal product is aimed for treatment
of disease, for which the number of patients eligible for
treatment with the medicinal product based on the indication
approved in marketing authorization was in the Slovak republic
lower than 1: 50,000.
The required dossiers obligatory in reimbursement
procedures should be submitted by the MAH and have to
include basic drug information, evidence on its effectiveness,
the standard therapeutic dose, and the number of standard
therapeutic doses per package. Applications also contain the
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proposed reimbursement rate, indication, and restriction of
prescription and/or indication, if applicable.
After a medicine receives market authorization, the Ministry
of Health of the Slovak Republic determines its maximum
retail price (ex-factory price), applying external reference pricing
methodology. The final price of each medicine available on
the Slovak pharmaceutical market may not exceed the average
of the three lowest prices of the same medicine available on
pharmaceutical markets across the EU. The Slovak Ministry
of Health established the Reimbursement (or Categorization)
Committee to act as its advisory body on reimbursement
processes. The Committee prepares recommendations for
reimbursement levels, patients’ co-payments, and conditions for
reimbursement. The decision about the reimbursement levels of
eligible medicines is based on the following criteria: therapeutic
benefit of the medicine; cost-effectiveness; and the reimbursed
levels of other medicines within the same reference group.
The final reimbursement (or categorization) list also includes
medicines with prescription or indication restrictions. In the case
of certain oncological medicines, the reimbursement can also be
restricted to prescription solely in specialized hospitals. Based on
the recommendations from the Categorization Committee the
Ministry of Health issues final decisions (Tables 2, 3).
DISCUSSION
The objective of this study was to provide a comprehensive
description of orphan drug reimbursement policies in EU–CEE
countries. Moreover, we aimed to assess the agreement in
reimbursement decisions between those countries as well as
the impact of the type of approval and disease (oncological or
metabolic) on reimbursement decisions. We observed that half
of the analyzed countries imposed specific regulations regarding
reimbursement of orphan drugs; however, none of the countries
used higher an ICER threshold (marginal costs per QALY) for
orphan drugs. The share of reimbursed orphan drugs varied
significantly across the countries; however, it was not significantly
associated with neither GDP not GDP per capita. The agreement
between the countries varied from slight agreement (Estonia
vs. Latvia) to substantial agreement (Estonia vs. Lithuania);
however, the agreement was also affected by the different shares
of reimbursed orphan drugs. Our study revealed that there are
differences in reimbursement and HTA policies across so called
Baltic countries. In Lithuania no formal HTA process has been
implemented; in Latvia no special laws or policies regarding
orphan drugs different from the ones for non-orphan drugs
are in force; in Lithuania the special policies apply only to
ultra-orphan drugs (defined as indicated for illnesses with a
prevalence of 1:200,000 or lower). The differences between those
countries could be also noticed from the perspective of burden
of healthcare on households’ budgets. The financial burden of
paying for medicines in 2017 in EU countries varied significantly
with Estonia being one of the countries with the smallest share of
households with high burden and Latvia and Lithuania being one
of the countries with the highest share of households with high
burden (European Commission, 2019).
In The Czechia, Lithuania and Slovakia, the reimbursement
statuses were significantly associated with the type of approval;
while in Croatia, Estonia, Hungary and Lithuania, the type
of disease was significantly associated with the reimbursement
status. In all those countries, most reimbursed drugs were
indicated for the treatment of oncological diseases.
In some countries limitations in reimbursement only for
some subgroups of patients due to budgetary constraints are
applicable; public coverage is limited only for patients fulfilling
some inclusion criteria e.g., stage or severity of disease.
To compare the results of our study with current knowledge
on the subject, we performed a systematic review of publications
in medical databases. We identified a study from 2016 by
Zelei et al. (2016), who reviewed scientific evidence on the
HTA of orphan drugs with a special focus on public payers
in CEE countries. The authors observed that only 5 of
87 publications included in the analysis referred to CEE
countries, which indicates the need for further research. As CEE
countries are more budget-restricted than western countries,
they could be more affected by the lack of clinical evidence
for orphan drugs, which generally gain marketing authorization
earlier than non-orphan drugs. Our present study showed
that the type of marketing authorization plays an important
role in many CEE countries. If the accessibility of orphan
drugs remains at the same level in the CEE region as in
western EU countries, the relative budget impact could be
significantly higher.
The study from 2012 by Iskrov et al. (2012) focused on
the perspective on Bulgaria in terms of reimbursement of
orphan drugs. The authors revealed that of all 61 orphan
drugs approved in the EU in 2011, only 16 were available
in Bulgaria and the mean waiting time for reimbursement
decision was 43 months (standard deviation, 29 months).
Similarly, to our study, the author emphasized the need for
special legislation for orphan drugs that are not only based on
epidemiological but, more importantly, on economic factors for
better assets allocation.
Pavlović et al. (2012) revealed that in 2012 in Bulgaria
the Positive Drug List included 44.3% (27 out of 61) of the
drugs with prior orphan designation, as compared with only
25% (17 out of 68) in Serbia and 52.5% (32 out of 61) in
Sweden, which also indicated a difference between Eastern and
Western part of Europe.
Logviss et al. (2014) evaluated a situation in Latvia in
2014. They revealed that 34 orphan drugs were available in
Latvia, although only three were reimbursed (all indicated
for Philadelphia chromosome–positive chronic myeloid
leukemia). Additionally, 15 drugs (44.1%) were reimbursed
for individual patients and another five drugs (14.7%) were
reimbursed as part of a medical treatment program for rare
diseases in children.
Picavet et al. (2012) analyzed access to orphan drugs
for almost all EU countries (except for Cyprus, Malta,
and Portugal) based on data from IMS Health (2011).
They showed that employing an HTA process plays an
important role in the patients’ access to reimbursed orphan
drugs, which mostly affect low-GDP countries. However,
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nowadays more low-GDP countries use a formal HTA
process than in 2011.
Gammie et al. (2015) analyzed regulations and policies
used by countries to allow patient access to orphan drugs in
2015 by performing a systematic review of evidence published
between 1998 and 2014. They summarized legislations of 35
countries from around the world, including 21 from the EU,
and revealed that a different type of special regulations for
orphan drugs (national orphan drug policies, orphan drug
designation, marketing authorization, marketing exclusivity, and
tax credits) was present in most of the countries. A variation
in the share of orphan drugs accessible for the patients
was also observed.
Kamusheva et al. (2018) provided a comprehensive
description of access of patients with rare diseases to
biotechnological drugs in several CEE countries in 2018, showing
that special legislation for orphan drugs was implemented in
several CEE countries. The share of accessible orphan drugs
as well as total expenditures varied across countries, being the
highest in Greece and the lowest in Romania.
Szegedi et al. (2018) revealed that from 29.4 to 92.8% of the
83 orphan drugs were available (and reimbursed) in 2015 in 8
EU countries in favor of the higher-income ones. The highest
expenditure on orphan drugs in the years from 2013 to 2014 was
observed in Belgium (245–280 million Euro) and the lowest in
Bulgaria (8.3–12.2 million Euro).
Another study assessed Bulgarian legislation on HTA
and reimbursement decision-making criteria, with a special
focus on orphan and innovative drugs. A critical analysis
of current decision-making criteria for drug reimbursement
was performed, and a comprehensive assessment scoring
system for orphan drugs with decision-making criteria was
scheduled, including the presence of therapeutic alternative,
clinical effectiveness, safety, pharmacoeconomics, and societal
value, which were divided into weighted indicators. The
study revealed that Bulgarian reimbursement decision-making
seems not to be sufficiently transparent and not effective in
innovative HTA, with access to a therapeutic alternative as a
key reimbursement decision-making criterion for orphan drugs
(Iskrov et al., 2013).
In the recent study Czech et al. (2018) compared rare
disease definitions and epidemiology, diagnostics and new-born
screening, national plans, patient registries and reimbursement
of orphan drugs including HTA processes in Poland, Russia,
and the Netherlands. There are clear differences in healthcare
expenditure and rare disease policies between these countries.
Access to reimbursed orphan drugs varies widely between these
three countries, and sometimes even within (Russia). Budgeting
structures (i.e., federal vs. regional) play a large role in regional
healthcare access for patients, especially in Russia, where local
government institutions and budgets often determine the type
and level of healthcare provided. These findings were confirmed
in our analyses.
In our previous study (Malinowski et al., 2018) we have
analyzed orphan drugs reimbursement policies in selected
Western European countries. We have observed that the
share of reimbursed orphan drugs is significantly higher in
Western Europe than in the CEE states however, the agreement
between countries has not present any spatial relationship
as in the current study. In both studies we have observed
a significant influence of both disease type and EMA drug
authorization type on reimbursement decisions in some
countries - conditional approval significantly decreased the
chance for reimbursement in France, Italy, and Spain by
77–80%; approval granted under exceptional circumstances
had significant impact only in Germany with 85% decrease
in chances for reimbursement. The different shares of
reimbursed drugs between previous and current studies
(which is an obvious finding) make comparisons of results of
both projects difficult.
Our study is the first to comprehensively analyse of the
impact of the type of EMA approval and the type of the
disease on orphan drug reimbursement decision-making, which
constitutes the major strength of this study. The results should aid
orphan drug management and policies in a number of countries,
including CEE countries. The current and updated review of
reimbursement decisions among countries and international
comparisons provide additional input for proper and effective
reimbursement decision-making. Moreover, we collected the data
in cooperation with a number of local experts familiar with
reimbursement policy in each country, so the input is worthwhile
and credible. There is an institutional regional cooperation
initiative worth mentioning based on a memorandum of
understanding signed by selected CEE countries called V4+
Fair and Affordable Pricing. Its ultimate goal is to develop and
harmonize methods of cooperation and negotiations with MAHs
concerning pricing and conditions for reimbursement of selected
health technologies with a special emphasis on the highest priced
drugs including orphan medicinal products. The objective is
to build an active institutional network, exchange of expertise
and experience in pricing and reimbursement and conduct
common health technology assessment aimed at facilitation
access to effective and affordable treatment solutions. In our
study we not only did the regulation analysis but measure the
regulatory agreement, as well as also try to find its possible
correlation with other factors as GDP of the countries. We
have applied κ coefficient to measure the extent of agreement
between countries that is above the random (at chance). In
addition, we used logistic regression to calculate odds for
positive reimbursement decision in association with the type
of the disease. Using those statistical methods is inevitable
strength of the study.
Our study has also some limitations. First of all, we analyzed
drugs with orphan designations granted in 2017. We also
collected data valid for 2017 due to changes in reimbursement
systems in included countries, so our results will need an
update in the coming years. Moreover, a constant monitoring of
reimbursement statuses in analyzed countries, with conclusions
on current trends in reimbursement decision-making for
orphan drugs would be especially beneficial - so the issue
needs further assessment and additional studies. Chances for
reimbursement in analyzed countries could be also affected by
the prevalence of the diseases, which should be tested during
further studies.
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CONCLUSION
The study revealed that some of the considered countries already
established separate regulations on reimbursement of orphan
drugs; in case of some of these countries higher ICER values
for orphans are used; in Lithuania and Romania, no formal
HTA process was employed. The share of reimbursed orphan
drugs varied significantly across the countries, but it was not
associated either with GDP or GDP per capita. The lowest (slight)
agreement in reimbursement decisions was observed between
Estonia and Latvia, and the highest (substantial) agreement,
between Estonia and Lithuania. In The Czechia, Lithuania and
Slovakia, EMA’s conditional approval significantly decreased the
chances for reimbursement. In Croatia, Estonia, Hungary, and
Lithuania, drugs for oncological diseases had significantly greater
chances for reimbursement.
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